Cancer research has long faced the “Blind Men and the Elephant” dilemma, a metaphor derived from an ancient Indian parable. In the story, several blind men each touch a different part of an elephant—its trunk, leg, ear, or tail—and conclude that the creature resembles a snake, tree, fan, or rope. Each perception is valid within its narrow scope but incomplete when viewed in isolation. Similarly, cancer research has often been fragmented, with investigators focusing on isolated molecular pathways, cellular behaviors, or clinical outcomes without fully connecting these pieces into a unified picture of the disease. This systematic review explores how integrative and multidisciplinary approaches are overcoming that fragmentation to reshape our understanding of cancer. Drawing on advances in systems biology, multi-omics technologies, artificial intelligence, and collaborative research frameworks, we illustrate how convergence across disciplines enables a more comprehensive view of tumor biology and therapeutic response. Major initiatives such as The Cancer Genome Atlas, pan-cancer analyses, and emerging computational platforms exemplify how data integration can reveal patterns invisible to single-dimension studies. By highlighting both the transformative potential and persistent challenges of such integration—ranging from data harmonization to interdisciplinary communication—we propose a roadmap toward a holistic, collaborative, and patient-centered paradigm in oncology. In doing so, we aim to move beyond the limitations of partial understanding toward a collective vision that more accurately reflects the complexity of cancer.

1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. doi: 10.3322/caac.21660

2. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: A looking glass for cancer? Nat Rev Cancer. 2012;12(5):323-334. doi: 10.1038/nrc3261

3. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: An evolving paradigm. Nat Rev Cancer. 2013;13(10):714-726. doi: 10.1038/nrc3599

4. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11): 1423-1437. doi: 10.1038/nm.3394

5. Kitano H. Cancer as a robust system: Implications for anticancer therapy. Nat Rev Cancer. 2004;4(3):227-235. doi: 10.1038/nrc1293

6. Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome Biol. 2017;18(1):83. doi: 10.1186/s13059-017-1215-1

7. Esteva A, Robicquet A, Ramsundar B, et al. A guide to deep learning in healthcare. Nat Med. 2019;25(1):24-29. doi: 10.1038/s41591-018-0316-z

8. Zhang Y, Wang P, Li X, et al. GABC: A comprehensive resource and Genome Atlas for Breast Cancer. Int J Cancer. 2021;148(4):988-994. doi: 10.1002/ijc.33347

9. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature. 2020;578(7793):82-93. doi: 10.1038/s41586-020-1969-6

10. Rozenblatt-Rosen O, Regev A, Oberdoerffer P, et al. The human tumor atlas network: Charting tumor transitions across space and time at single-cell resolution. Cell. 2020;181(2):236-249. doi: 10.1016/j.cell.2020.03.053

11. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011;144(5):646-674. doi: 10.1016/j.cell.2011.02.013

12. Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013;501(7467):346-354. doi: 10.1038/nature12626

13. Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol. 2012;30(7):679-692. doi: 10.1038/nbt.2284

14. Barabási AL, Gulbahce N, Loscalzo J. Network medicine: A network-based approach to human disease. Nat Rev Genet. 2011;12(1):56-68. doi: 10.1038/nrg2918

15. Kitano H. Systems biology: A brief overview. Science. 2002;295(5560):1662-1664. doi: 10.1126/science.1069492

16. Ideker T, Krogan NJ. Differential network biology. Mol Syst Biol. 2012;8:565. doi: 10.1038/msb.2011.99

17. Saez-Rodriguez J, MacNamara A, Cook S. Modeling signaling networks to advance new cancer therapies. Annu Rev Biomed Eng. 2015;17:143-163. doi: 10.1146/annurev-bioeng-071813-104927

18. Chen L, Liu R, Liu ZP, et al. Detecting early-warning signals for sudden deterioration of complex diseases by dynamical network biomarkers. Sci Rep. 2012;2:342. doi: 10.1038/srep00342

19. Gavish A, Tyler M, Greenwald AC, et al. Hallmarks of transcriptional intratumour heterogeneity across a thousand tumours. Nature. 2023;618(7965):598-606. doi: 10.1038/s41586-023-06130-4

20. Cieslik M, Chinnaiyan AM. Global genomics project unravels cancer’s complexity at unprecedented scale. Nature. 2020;578(7793):39-40. doi: 10.1038/d41586-020-00213-2

21. Hoadley KA, Yau C, Hinoue T, et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types. Cell. 2018;173(2):291-304.e6. doi: 10.1016/j.cell.2018.03.022

22. Sanchez-Vega F, Mina M, Armenia J, et al. Oncogenic signaling pathways in The Cancer Genome Atlas. Cell. 2018;173(2):321-337.e10. doi: 10.1016/j.cell.2018.03.035

23. Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350-1356. doi: 10.1038/nm.3967

24. Marcus L, Donoghue M, Aungst S, et al. FDA approval summary: Entrectinib for the treatment of NTRK gene fusion solid tumors. Clin Cancer Res. 2021;27(4):928-932. doi: 10.1158/1078-0432.CCR-20-2771

25. Shalem O, Sanjana NE, Zhang F. High-throughput functional genomics using CRISPR-Cas9. Nat Rev Genet. 2015;16(5):299-311. doi: 10.1038/nrg3899

26. Hoffman GR, Rahal R, Buxton F, et al. Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers. Proc Natl Acad Sci U S A. 2014;111(8):3128-3133. doi: 10.1073/pnas.1316793111

27. Topol EJ. High-performance medicine: The convergence of human and artificial intelligence. Nat Med. 2019;25(1):44-56. doi: 10.1038/s41591-018-0300-7

28. Kather JN, Heij LR, Grabsch HI, et al. Pan-cancer image-based detection of clinically actionable genetic alterations. Nat Cancer. 2020;1(8):789-799. doi: 10.1038/s43018-020-0087-6

29. Lu MY, Chen TY, Williamson DFK, et al. AI-based pathology predicts origins for cancers of unknown primary. Nature. 2021;594(7861):106-110. doi: 10.1038/s41586-021-03512-4

30. Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550-1558. doi: 10.1038/s41591-018-0136-1

31. Mascheroni P, Savvopoulos S, Alfonso JCL, Meyer- Hermann M, Hatzikirou H. Improving personalized tumor growth predictions using a Bayesian combination of mechanistic modeling and machine learning. Commun Med (Lond). 2021;1:19. doi: 10.1038/s43856-021-00020-4

32. Wang Z, Butner JD, Kerketta R, Cristini V, Deisboeck TS. Simulating cancer growth with multiscale agent-based modeling. Semin Cancer Biol. 2015;30:70-78. doi: 10.1016/j.semcancer.2014.04.001

33. Zhavoronkov A, Ivanenkov YA, Aliper A, et al. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nat Biotechnol. 2019;37(9):1038-1040. doi: 10.1038/s41587-019-0224-x

34. Selby P, Popescu R, Lawler M, Butcher H, Costa A. The value and future developments of multidisciplinary team cancer care. Am Soc Clin Oncol Educ Book. 2019;39:332-340. doi: 10.1200/EDBK_236857

35. Curigliano G, Banerjee S, Cervantes A, et al. Managing cancer patients during the COVID-19 pandemic: An ESMO multidisciplinary expert consensus. Ann Oncol. 2020;31(10):1320-1335. doi: 10.1016/j.annonc.2020.07.010

36. Sahu A, Oh Y, Peterson G, et al. In vivo optical imaging-guided targeted sampling for precise diagnosis and molecular pathology. Sci Rep. 2021;11:23124. doi: 10.1038/s41598-021-01447-4

37. Boehm JS, Jacks T. Radical collaboration: Reimagining cancer team science. Cancer Discov. 2024;14(4):563-568. doi: 10.1158/2159-8290.CD-23-1496

38. June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(1):64-73. doi: 10.1056/NEJMra1706169

39. Peng Y, Lee E. Microphysiological systems for cancer immunotherapy research and development. Adv Biol (Weinh). 2024;8(8):e2300077. doi: 10.1002/adbi.202300077

40. Miotto R, Wang F, Wang S, Jiang X, Dudley JT. Deep learning for healthcare: Review, opportunities and challenges. Brief Bioinform. 2018;19(6):1236-1246. doi: 10.1093/bib/bbx044

41. Grossman RL. Data lakes, clouds, and commons: A review of platforms for analyzing and sharing genomic data. Trends Genet. 2019;35(3):223-234. doi: 10.1016/j.tig.2018.12.006

42. Sansone SA, Rocca-Serra P, Field D, et al. Toward interoperable bioscience data. Nat Genet. 2012;44(2):121-126. doi: 10.1038/ng.1054

43. Knoppers BM, Thorogood AM. The Human Genome Organisation: Towards next-generation ethics. Genome Med. 2013;5:38. doi: 10.1186/gm442

44. Urquhart R, Grunfeld E, Jackson L, Sargeant J, Porter GA. Cross-disciplinary research in cancer: An opportunity to narrow the knowledge-practice gap. Curr Oncol. 2013;20(6):e512-e521. doi: 10.3747/co.20.1487

45. Chen IY, Pierson E, Rose S, Joshi S, Ferryman K, Ghassemi M. Ethical machine learning in healthcare. Annu Rev Biomed Data Sci. 2021;4:123-144. doi:10.1146/annurev-biodatasci-092820-114757

46. Wilkinson MD, Dumontier M, Aalbersberg IJ, et al. The FAIR Guiding Principles for scientific data management and stewardship. Sci Data. 2016;3:160018. doi: 10.1038/sdata.2016.18

47. Hall KL, Stipelman BA, Vogel AL, et al. A four-phase model of transdisciplinary team-based research: Goals, team process and strategies. Am J Prev Med. 2012;42(2):159-169.

48. Subramanian I, Verma S, Kumar S, Jere A, Anamika K. Multi-omics data integration, interpretation, and its application. Bioinform Biol Insights. 2020;14:1177932219899051. doi: 10.1177/1177932219899051

49. Mertins P, Mani DR, Ruggles KV, et al. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature. 2016;534(7605):55-62. doi: 10.1038/nature18003

50. Zhang B, Wang J, Wang X, et al. Proteogenomic characterization of human colon and rectal cancer. Nature. 2014;513(7518):382-387. doi: 10.1038/nature13438

51. Akbani R, Ng PKS, Werner HMJ, et al. A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat Commun. 2014;5:3887. doi: 10.1038/ncomms4887

52. Huang KL, Mashl RJ, Wu Y, et al. Pathogenic germline variants in 10,389 adult cancers. Cell. 2018;173(2):355-370.e14. doi: 10.1016/j.cell.2018.03.039

53. Du W, Elemento O. Cancer systems biology: Embracing complexity to develop better anticancer therapeutic strategies. Oncogene. 2015;34(25):3215-3225. doi: 10.1038/onc.2014.291

54. Wei L, Niraula D, Gates EDH, et al. Artificial intelligence (AI) and machine learning (ML) in precision oncology: A review on enhancing discoverability through multiomics integration. Br J Radiol. 2023;96(1150):20230211. doi: 10.1259/bjr.20230211

55. Grossman RL, Heath AP, Ferretti V, et al. Toward a shared vision for cancer genomic data. N Engl J Med. 2016;375(12):1109-1112 doi: 10.1056/NEJMp1607591

56. Hanahan D. Hallmarks of cancer: New dimensions. Cancer Discov. 2022;12(1):31-46. doi: 10.1158/2159-8290.CD-21-1059

57. Yankeelov TE, An G, Saut O, et al. Multi-scale modeling in clinical oncology: Opportunities and barriers to success. Ann Biomed Eng. 2016;44(9):2626-2641. doi: 10.1007/s10439-016-1691-6

58. Huang S. Reconciling non-genetic plasticity with somatic evolution in cancer. Trends Cancer. 2021;7(4):309-322. doi: 10.1016/j.trecan.2020.12.007

59. Alix-Panabières C, Pantel K. Liquid biopsy: From discovery to clinical application. Cancer Discov. 2021;11(4):858-873. doi: 10.1158/2159-8290.CD-20-1311

60. Vis DJ, Lewin J, Liao RG, et al. Towards a global cancer knowledge network: Dissecting the current international cancer genomic sequencing landscape. Ann Oncol. 2017;28(5):1145-1151. doi: 10.1093/annonc/mdx037

61. Shriver SP, Adams D, McKelvey BA, et al. Overcoming barriers to discovery and implementation of equitable pharmacogenomic testing in oncology. J Clin Oncol. 2024;42(10):1181-1192. doi: 10.1200/JCO.23.01748

62. Cruz Rivera S, Aiyegbusi OL, Ives J, et al. Ethical considerations for the inclusion of patient-reported outcomes in clinical research: The PRO Ethics Guidelines. JAMA. 2022;327(19):1910-1919. doi: 10.1001/jama.2022.6421

63. Macklin P. Key challenges facing data-driven multicellular systems biology. J Physiol. 2017;595(9):2897-2904. doi: 10.1113/JP273037

64. Hutter C, Zenklusen JC. The cancer genome atlas: Creating lasting value beyond its data. Cell. 2018;173(2):283-285. doi: 10.1016/j.cell.2018.03.042

65. Wing C, Simon K, Bello-Gomez RA. Designing difference in difference studies: Best practices for public health policy research. Annu Rev Public Health. 2018;39:453-469. doi: 10.1146/annurev-publhealth-040617-014507

66. Azoulay L. Rationale, Strengths, and limitations of real-world evidence in oncology: A Canadian review and perspective. Oncologist. 2022;27(9):e731-e738. doi: 10.1093/oncolo/oyac114

67. Errington TM, Denis A, Perfito N, Iorns E, Nosek BA. Challenges for assessing replicability in preclinical cancer biology. eLife. 2021;10:e67995. doi: 10.7554/eLife.67995

68. Vogel AL, Knebel AR, Faupel-Badger JM, Portilla LM, Simeonov A. A systems approach to enable effective team science from the internal research program of the National Center for Advancing Translational Sciences. J Clin Transl Sci. 2021;5(1):e163. doi: 10.1017/cts.2021.811

69. Hall KL, Vogel AL, Stipelman BA, et al. The science of team science: A review of the empirical evidence and research gaps on collaboration in science. Am Psychol. 2018;73(4):532-548. doi: 10.1037/amp0000319

70. Barkley D, Moncada R, Pour M, et al. Cancer cell states recur across tumor types and form specific interactions with the tumor microenvironment. Nat Genet. 2022;54:1192-1201. doi: 10.1038/s41588-022-01141-9

71. Jordan MI, Mitchell TM. Machine learning: Trends, perspectives, and prospects. Science. 2015;349(6245):255-260. doi: 10.1126/science.aaa8415

72. Doria-Rose VP, Greenlee RT, Buist DSM, et al. Collaborating on data, science, and infrastructure: The 20-year journey of the cancer research network. EGEMS (Wash DC). 2019;7(1):7. doi: 10.5334/egems.273

73. Jensen MA, Ferretti V, Grossman RL, Staudt LM. The NCI Genomic Data Commons as an engine for precision medicine. Blood. 2017;130(4):453-459. doi: 10.1182/blood-2017-03-735654